Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Journal: Expert review of hematology
Published: May 27, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.
Journal: Current oncology (Toronto, Ont.)
Published: March 17, 2026
Correction: Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Journal: PloS one
Published: March 31, 2017
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Journal: Blood cancer journal
Published: September 17, 2016
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).
Journal: Blood cancer journal
Published: March 26, 2016
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 28, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 07, 2015
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Journal: Leukemia
Published: December 15, 2014
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.
Journal: Leukemia
Published: November 24, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: November 22, 2014
Last Updated: 09/26/2026